Comparative Pharmacology
Head-to-head clinical analysis: INH versus SODIUM AMINOSALICYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INH versus SODIUM AMINOSALICYLATE.
INH vs SODIUM AMINOSALICYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
INH inhibits InhA, an enoyl-acyl carrier protein reductase involved in mycolic acid synthesis, essential for the mycobacterial cell wall. It also disrupts NAD and NADH metabolism via the KatG-activated isonicotinoyl-NAD adduct.
Sodium aminosalicylate inhibits folic acid synthesis in Mycobacterium tuberculosis by competing with para-aminobenzoic acid (PABA) for the enzyme dihydropteroate synthase, thereby blocking bacterial growth.
300 mg orally once daily (or 15 mg/kg orally once daily, up to 300 mg total) for active tuberculosis; for latent tuberculosis, 300 mg orally once daily or 900 mg orally twice weekly under directly observed therapy.
4 g orally three times daily (total daily dose 12 g) for tuberculosis treatment. Also available as 10 g in 250 mL for intravenous infusion over 5-6 hours, typically once daily.
None Documented
None Documented
Fast acetylators: 0.5-1.5 hours; slow acetylators: 2-4 hours. Clinically, slow acetylators have higher risk of peripheral neuropathy and hepatotoxicity.
0.75-1.5 hours (parent drug); prolongs to 4-6 hours in renal impairment or with probenecid coadministration. Rapid acetylation phenotype reduces half-life by ~30%.
Renal: 75-95% as unchanged drug and metabolites (including acetylisoniazid, isonicotinic acid). Biliary/fecal: minor (<5%).
Renal: >80% as metabolites (acetylated and free), with 50-60% as N-acetyl-4-aminosalicylic acid; biliary/fecal: <1%.
Category C
Category C
Antitubercular Agent
Antitubercular Agent